27,570 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas bought a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 27,570 shares of the medical device company's stock, valued at approximately $993,000.

Other large investors have also made changes to their positions in the company. Brooklyn Investment Group acquired a new position in Tandem Diabetes Care in the third quarter valued at about $28,000. AlphaQuest LLC boosted its holdings in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares in the last quarter. Jones Financial Companies Lllp grew its position in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after acquiring an additional 748 shares during the last quarter. Assetmark Inc. increased its holdings in Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares in the last quarter. Finally, McIlrath & Eck LLC acquired a new stake in Tandem Diabetes Care during the 3rd quarter valued at $52,000.

Tandem Diabetes Care Stock Down 1.3 %

Shares of Tandem Diabetes Care stock traded down $0.24 on Tuesday, hitting $18.92. The company had a trading volume of 339,566 shares, compared to its average volume of 1,470,978. Tandem Diabetes Care, Inc. has a twelve month low of $17.64 and a twelve month high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock has a 50-day moving average of $27.76 and a 200-day moving average of $32.79. The firm has a market capitalization of $1.26 billion, a P/E ratio of -9.84 and a beta of 1.45.

Remove Ads

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The shares were acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.20% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on TNDM. Royal Bank of Canada decreased their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Barclays decreased their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Robert W. Baird dropped their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Canaccord Genuity Group reissued a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company reissued an "equal weight" rating and issued a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $45.38.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.